Structure Therapeutics (NASDAQ:GPCR) Issues Earnings Results

Structure Therapeutics (NASDAQ:GPCR) posted its quarterly earnings data on Thursday. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.01, Zacks reports.

Structure Therapeutics Stock Performance

NASDAQ:GPCR traded up $1.12 during mid-day trading on Friday, hitting $23.94. The company had a trading volume of 504,948 shares, compared to its average volume of 788,562. Structure Therapeutics has a fifty-two week low of $19.61 and a fifty-two week high of $62.74. The firm has a market cap of $1.37 billion, a P/E ratio of -32.22 and a beta of -2.75. The business’s fifty day moving average is $26.66 and its two-hundred day moving average is $33.66.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. JMP Securities reissued a “market outperform” rating and issued a $91.00 price target on shares of Structure Therapeutics in a report on Wednesday, December 18th. William Blair initiated coverage on Structure Therapeutics in a research note on Friday. They issued an “outperform” rating for the company. HC Wainwright reaffirmed a “buy” rating and set a $80.00 price target on shares of Structure Therapeutics in a research note on Thursday, December 19th. Finally, Stifel Nicolaus initiated coverage on Structure Therapeutics in a research report on Wednesday, January 8th. They issued a “buy” rating and a $50.00 price objective for the company. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $81.29.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.